Someone please correct me if I am wrong as I am not a scientist. But Ruxolitinib is a cancer treatment where the MOA is stopping cancer cells from splitting and multiplying. It has very negative side effects.
How would a trial using this type of drug (Ruxolitinib) have any bearing on a cellular therapy where the MOA is to reduce inflammation and cykotine storms (MSB), with little to no side effects.
Just because the trial is on the same cohort does the op think it has a bearing on MSBs cellular therapies outcomes? It won't.
Why have HCs mods allowed this thread to even be posted in the MSB forum?
Someone please correct me if I am wrong as I am not a scientist....
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.010(0.92%) |
Mkt cap ! $1.233B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.11 | $1.05 | $5.002M | 4.632M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5697 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
-0.010 ( 0.10 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.11 | $1.06 | 1181223 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| MSB (ASX) Chart |